TRANSFORMING THE TREATMENT OF LIVER DISEASE

Morphocell Technologies is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating liver diseases.
ReLiver™â€‹
Morphocell Technologies’ ReLiver™ is an engineered liver tissue that performs like the human liver.
Morphocell Technologies is developing ReLiver™ into 3 different products:

ReLiver™ELT
An implantable device capable of restoring liver functions in patients with acute and acute-on-chronic liver failure. ReLiver™ELT is already in advanced pre-clinical assessment

ReLiver™BALD
An extracorporeal bio-artificial liver device aimed at treating not only patients with acute, but also the tens of millions of patients with chronic liver

ReLiver™Assay
An in vitro assay for next-generation drug discovery. As a more representative model of the human liver, ReLiver™Assay helps reducing drug failures in the clinical phases.
Acute Liver Failure
-
Qualifies as a rare disease with an incidence of <1/100,000 per year​​
​
-
Liver transplantation is the only cure (62% overall survival, <50% for infants​
-
Acute liver failure accounts for >1000 deaths/year in the United States​
-
Up to 80% of patients with ALF could avoid transplantation if temporary replacement of liver functions could be assured while their own liver regenerates.
Through cutting-edge approaches of tissue engineering, Morphocell Technologies is developing revolutionary products targeting currently untreatable liver diseases.

Deaths caused by liver disease worldwide
>1 MILLION/year

Acute liver failure: survival rate without liver transplant
<50%
NEWS

CONTACT US
+1 (514) 345 4931 ext. 7879
c/o CHU Sainte-Justine Research Center
3175 Ch. Côte-Sainte-Catherine
Montreal, QC, H3T 1C5
Canada